K-7174K-7174
MedChemExpress (MCE)
HY-12743
191089-59-5
98.02%
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Room temperature in continental US
may vary elsewhere.
K-7174 is an orally active proteasome and GATA inhibitor. K-7174 is a cell adhesion inhibitor. K-7174 induces cell apoptosis. K-7174 shows antitumor activities, it can be used for the research of cancer.
K-7174 (10 μM
1 h) inhibits the adhesion by VCAM-1 and its ligand[1]. K-7174 (1-30 μM
1 h) dose-dependently suppresses the VCAM-1 expression with an IC50 value of 14 μM[1]. K-7174 (1-30 μM
1 h) dose-dependently suppresses the induction of VCAM-1 mRNA by TNFα with an IC50 value of 9 μM[1]. K-7174 (10-20 μM
24 h) dose-dependently rescues Epo production by Hep3B cells[2]. K-7174 (2.5-30 μM
24 h) inhibits the binding activity of GATA[2]. K-7174 (0-25 μM
72 h) inhibits MM cells growth and induces cell apoptosis[3].
K-7174 (30 mg/kg
i.p. once daily for 9 days) reverses the decreasing of hemoglobin concentrations and reticulocyte counts by IL-1β or TNF-α[2]. K-7174 (75 mg/kg
i.p. once daily for 14 days) inhibits the tumor growth in vivo[3]. K-7174 (50 mg/kg
p.o. once daily for 14 days) inhibits the tumor growth in vivo and shows a better effect than intraperitoneal injection[3].
| | | |
| | | | | |
[1]. Umetani M, et al. A novel cell adhesion inhibitor, K-7174, reduces the endothelial VCAM-1 induction by inflammatory cytokines, acting through the regulation of GATA. Biochem Biophys Res Commun. 2000 Jun 7
272(2):370-4. [Content Brief]
[2]. Imagawa S, et al. A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. FASEB J. 2003 Sep
17(12):1742-4. [Content Brief]
[3]. Kikuchi J, et al. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases. J Biol Chem. 2013 Aug 30
288(35):25593-602. [Content Brief]